SNCA antibody (Middle Region)
Quick Overview for SNCA antibody (Middle Region) (ABIN2775366)
Target
See all SNCA AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- Middle Region
-
Sequence
- VTNVGGAVVT GVTAVAQKTV EGAGSIAAAT GFVKKDQLGK EGYQDYEPEA
-
Predicted Reactivity
- Cow: 100%, Dog: 100%, Guinea Pig: 100%, Horse: 100%, Human: 100%, Mouse: 100%, Rabbit: 100%, Rat: 100%, Sheep: 100%
-
Characteristics
- This is a rabbit polyclonal antibody against SNCA. It was validated on Western Blot using a cell lysate as a positive control.
-
Purification
- Affinity Purified
-
Immunogen
- The immunogen is a synthetic peptide directed towards the middle region of human SNCA
-
-
-
-
Application Notes
- Optimal working dilutions should be determined experimentally by the investigator.
-
Comment
-
Antigen size: 112 AA
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- Lot specific
-
Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freeze-thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
- SNCA (Synuclein, alpha (SNCA))
-
Alternative Name
- SNCA
-
Background
-
Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease.Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced transcripts of SNCA have been identified. Additional splicing may be present but the full-length nature of these variants has not been determined.
Alias Symbols: MGC110988, NACP, PARK1, PARK4, PD1
Protein Interaction Partner: NEDD4L, UBC, NEDD4, SNCA, GAPDH, HPRT1, CHMP5, KLK6, PARK7, LAMP2, CDC5, SLG1, PLK2, SAC7, TUS1, ROM2, MID2, Csnk2b, Lyn, Fgr, Csnk1g3, Syk, Rab5a, YWHAQ, ARPP19, RABAC1, TUBA1B, CALM, ACTA1, HIST2H3C, TUBB1, BDH2, USP47, SAP30BP, PELP1, SIN3A, Rab3a, ENC
Protein Size: 112 -
Molecular Weight
- 11 kDa
-
Gene ID
- 6622
-
NCBI Accession
- NM_007308, NP_009292
-
Pathways
- Synaptic Membrane, Regulation of G-Protein Coupled Receptor Protein Signaling, Positive Regulation of Endopeptidase Activity, Regulation of Carbohydrate Metabolic Process, Platelet-derived growth Factor Receptor Signaling, Negative Regulation of Transporter Activity, Regulation of long-term Neuronal Synaptic Plasticity
Target
-